Clinical Trial

Safety and Feasibility Study of the MitraFix® Transcatheter Mitral Valve System

Study acronym: MITRA-EFS
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this early feasibility clinical trial is to test a new device called the MitraFix® Transcatheter Mitral Valve System. It aims to learn if the device is safe and if it can help adults who have a severe leaky heart valve (mitral regurgitation). This study is for people who are at high risk for traditional open-heart surgery. The main questions it aims to answer are: Is the MitraFix system safe for participants? Can the device be successfully placed in the heart? Does the device help reduce the valve leak and improve daily life? Participants will: Receive the MitraFix valve through a small tube inserted into a vein in the leg. Visit the clinic for heart tests, walking tests, and health checks for up to one year after the procedure.
Trial Details
NCT Number NCT07501234
Lead Sponsor Mitrassist Lifesciences Limited Co., Ltd.
Conditions Mitral Regurgitation (MR)
Enrollment 5 participants
Start Date 2026-03-23
Primary Completion 2028-03-23 (estimated)
Study Completion 2028-10-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-30